Source: Drug Discovery & Development
The European Commission has given marketing authorization to GlaxoSmithKline for two doses of the Cervarix vaccine to protect girls ages 9 to 14 from cervical cancer. This is the first cervical cancer vaccine approved with a lower dosing schedule. The vaccine will continue to be offered in a three-dose schedule to girls ages 15 and older. “This new dosing schedule can make vaccination easier to implement and more affordable, which in turn creates the potential for higher vaccination coverage and more girls being protected against cervical cancer,” says Thomas Breuer of GSK Vaccines. Cervarix is already approved in the United States, and the two-dose schedule for 9- to 14-year-old girls has been approved in 12 countries.